Seeking a CRO? Do This First.

By Réne Stephens, Managing Director, Clinical Business Operations

Deciding on the right Contract Research Organization (CRO) is critical to your clinical trial success. However, many biopharma sponsors start the selection process without first engaging an outsourcing specialist. Unlike larger biopharma companies with in-house teams managing the outsourcing process, smaller organizations typically go without this specialized role. This can lead to a host of pitfalls and long-term consequences that may jeopardize your study.

  • Incorrect fit. Like an outfit bought in haste, without an expert outsourcing “tailor,” executives or clinical teams may take the easy route by opting for a well-known, large CRO or one that has been recommended by a colleague or friend. While this seems like the path of least resistance, it may not always result in the best fit for the specific needs of the trial. Without proper analysis, you risk selecting a CRO that is too large or too small, or one that lacks critical capabilities your trial requires.
  • Knowledge of CRO Landscape. Outsourcing specialists have their finger on the pulse of the CRO market. Without their involvement, executives may simply not know the full range of options. The CRO industry is vast, and new, innovative providers frequently emerge that may offer better capabilities, specialized expertise, or more cost-effective solutions. Without a specialist, sponsors often end up with suboptimal choices, missing out on better suited options.
  • Clinical Operations Teams Have Different Priorities. Clinical operations teams rightly focus on study execution more than strategic alignment of outsourcing needs. They may not have the same objectives when it comes to due diligence and contract negotiations as someone in a procurement or outsourcing role. Clinical operations teams might prioritize operational efficiency and technical compatibility but overlook critical elements such as pricing structure, risk-sharing models, and quality guarantees. This could lead to a bad deal where the sponsor ends up overpaying or agrees to unfavorable contract terms, creating financial and operational strain down the line.
  • Due Diligence Gaps. CRO selection is a complex process that goes beyond assessing basic capabilities. Without the rigorous vetting process that an outsourcing specialist provides, due diligence may be insufficient. Experts in the field guide teams through the process, ensuring a more robust and thorough analysis and freeing clinical operations teams so their focus remains on core delivery capabilities.  These areas of diligence are more than just box-checking exercises as they provide the underlying rationale to support selection decisions when compliance, regulators, and/or auditors come calling.
  • Poor Negotiation Outcomes. Negotiating with a CRO without the guidance of an outsourcing expert often results in missed opportunities to optimize the contract. Outsourcing specialists have experience in understanding industry standards, negotiating flexible terms, and securing competitive pricing. Without their expertise, sponsors may lock themselves into contracts with rigid timelines, lack of milestones, or high financial penalties, ultimately reducing the sponsor’s leverage in managing the trial effectively.
  • Conflicts of Interest: A common but often overlooked issue is when a CEO, executive, or key decision-maker favors working with a specific CRO due to personal connections—such as a recommendation from a colleague or a previous working relationship. While these relationships may seem beneficial initially, they can lead to a bias in the decision-making process, where the CRO’s past reputation or personal relationship takes precedence over actual suitability for the current trial.

How an Outsourcing Specialist Can Help

Outsourcing specialists bring an objective, data-driven approach to CRO selection. They know how to evaluate CROs based on key indicators like performance metrics, therapeutic area expertise, geographic reach, regulatory success, and financial stability. Their primary role is to ensure that the CRO selected is the best possible match for the specific needs of your trial, not just the most convenient or familiar option.

  • Broader Market Knowledge: Outsourcing specialists have a comprehensive view of the CRO market, ensuring that all potential providers are evaluated, from large global CROs to niche, specialized players.
  • Stronger Contracts: They bring the experience necessary to negotiate contracts that protect the sponsor, with favorable terms, performance guarantees, and clear, measurable milestones.
  • Aligned Interests: An outsourcing specialist ensures that the goals of the sponsor—whether speed to market, cost control, or quality—are the priority during the entire CRO selection and contracting process.
  • Risk Mitigation: With their focus on due diligence, they reduce the risk of selecting a CRO with inadequate capabilities or poor track records.

The takeaway? Engaging an outsourcing specialist before selecting your CRO is not an added expense—it’s an investment in the success of your clinical trial. The pitfalls of not doing so are many: from selecting a misaligned CRO, to signing unfavorable contracts, to experiencing costly delays. Ultimately, an outsourcing specialist acts as a vital guide through the complex landscape of CRO selection, ensuring the trial runs smoothly and efficiently, and reducing the risk of costly errors.

In today’s competitive clinical trial landscape, where every decision can impact time-to-market, quality of data, and financial stability, engaging an outsourcing specialist is essential to achieving your goals. 

Click here to learn more.

Danforth Advisors Acquires Advyzom

Establishes Complete Range of Clinical and Regulatory Services for Life Science Companies

WALTHAM, Mass.– September 10, 2024 – Danforth Advisors, LLC, today announced the acquisition of Advyzom, LLC, a leading regulatory affairs consultancy, creating a single, comprehensive resource for life science companies to access the expertise required on the path to proof-of-concept, regulatory approval, and market entry.

Danforth’s clinical and regulatory bench now spans experts across preclinical and medical advisory, clinical development operations, regulatory strategy, FDA liaisons and submissions, medical writing, and clinical and CMC outsourcing. By assembling the critical functions of asset development under one roof, Danforth maximizes operational efficiency for life science companies and applies the benefit of deep institutional knowledge across key roles.  

Founded in 2011, Advyzom comprises approximately 30 specialists with backgrounds in biotechnology and big pharma, providing expertise in global regulatory strategy, FDA relationships as US agents, document publishing,  regulatory submissions, and medical writing. The team serves as a primary interface to health authorities and has led or supported the achievement of hundreds of regulatory milestones for clients, including INDs, NDA/BLA filings and approvals, and numerous FDA designations to expedite development and approval. Founder and CEO Cindy Dinella will continue in her leadership role.

“Advyzom brings top talent and an exceptional track record in regulatory strategy, timely execution, and positive working relationships with health authorities – all critical to achieving clients’ drug development and commercialization objectives. We now have a fully integrated suite of clinical and regulatory services that can adapt to every stage of development,” said Chris Connors, CEO of Danforth Advisors. “More broadly, this latest acquisition advances our vision to be an agile foundation for life science companies – providing the variable teams and skill sets they need to run the business, develop assets, and launch products.”

“We are privileged to work with pioneering innovators to help much-needed treatments reach patients, and in Danforth we found a team that shares our passion for this cause,” said Dr. Dinella. “We are excited for the opportunity to partner with more life science companies who require thoughtful leaders and hands-on collaborators to navigate the regulatory landscape across the development journey.”

Advyzom is the fourth organization to join Danforth, following the acquisitions of BW Health Group in 2024, Elite BioPharma Consulting in 2023, and Argot Partners in 2022. In December 2021, Danforth announced an investment by Avesi Partners, LLC, to accelerate plans to meet an ever-broadening scope of strategic and operational needs for life science companies.

About Advyzom

Advyzom is a leading boutique consulting company specializing in highly strategic regulatory and development advice and services for clients in the pharmaceutical and healthcare industries. The company is headquartered in New Jersey and supports the development programs of clients at all stages as a virtual or embedded extension of their teams. Additional information is available at www.advyzom.com.

About Danforth Advisors

Danforth is the life science industry’s trusted partner for strategic and operational support across corporate, clinical, and commercial functions. The company advises and executes in the areas of finance and accounting, strategic communications, human resources, risk management, clinical and regulatory, and commercial readiness and launch. Founded in 2011, Danforth has partnered with more than 1,000 life science companies, private and public, across all stages of the corporate lifecycle. The company serves clients around the globe from its base in Waltham, Massachusetts and regional operations in New York, Pennsylvania, Maryland, California, and London.